Oxidative stress in Graves' disease patients and antioxidant protection against lymphocytes DNA damage in vitro.
DNA damage to peripheral blood lymphocytes of patients with Graves' disease (GD) was studied in vitro before and after treatment with antioxidants, melatonin, quercetin, N-acetylcysteine (NAC) and vitamin C. DNA damage (comet %) was remarkably higher in patients (23.7 +/- 5.5%) than that in healthy persons (9.8 +/- 3.2%, p < 0.01). Plasma malondialdehyde (MDA) content (7.90 +/- 1.77 microM) of patients was significantly higher than that of healthy persons (4.71 +/- 1.19 microM, p < 0.01). Also, the plasma total antioxidant capacity (TAC) (7.53 +/- 1.35 U/ml) in GD patients was significantly lower than that in healthy persons (10.56 +/- 2.21 U/ml, p < 0.01). Negative correlations were observed between plasma TAC and DNA damage in lymphocytes (r = -0.599, p < 0.01), and between plasma TAC and MDA (r = -0.40, p < 0.05) in GD patients. After treatment with 100 microM melatonin, quercetin or NAC for 4 h in vitro, DNA damage in lymphocytes in GD patients declined significantly (from 23.8 +/- 4.4% to 14.4 +/- 4.0%, p < 0.001 for melatonin, from 23.4 +/- 4.7% to 18.1 +/- 4.3%, p < 0.01 for quercetin, from 23.7 +/- 4.0% to 18.7 +/- 5.7%, p < 0.05 for NAC), while there was little change with concentrations of 1-100 microM of vitamin C. However, 1000 microM vitamin C enhanced DNA damage significantly (from 23.8 +/- 2.3% to 30.3 +/- 3.9%, p < 0.05). Our results showed that oxidative stress existed in GD patients and the antioxidants melatonin, quercetin and NAC are beneficial for DNA damage in lymphocytes of GD patients in vitro.
Tang
Xu-Lei
XL
School of Life Sciences, Lanzhou University, China.
Liu
Xiao-Ju
XJ
Sun
Wei-Ming
WM
Zhao
Jin
J
Zheng
Rong-Liang
RL
D000111:Acetylcysteine / Q000494:pharmacology; D000328:Adult; D000975:Antioxidants / Q000494:pharmacology*; D001205:Ascorbic Acid / Q000494:pharmacology; D020552:Comet Assay; D004249:DNA Damage / Q000187:drug effects*; D005260:Female; D006111:Graves Disease / Q000378:metabolism*; D006801:Humans; D007202:Indicators and Reagents; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008550:Melatonin / Q000494:pharmacology; D018384:Oxidative Stress / Q000187:drug effects*; D011794:Quercetin / Q000494:pharmacology; D013961:Thyroid Gland / Q000187:drug effects / Q000502:physiology; D013972:Thyrotropin / Q000494:pharmacology; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D000975:Antioxidants; D007202:Indicators and Reagents; D014284:Triiodothyronine; D008315:Malondialdehyde; D013972:Thyrotropin; D011794:Quercetin; D008550:Melatonin; D001205:Ascorbic Acid; D013974:Thyroxine; D000111:Acetylcysteine